Registration Number
0216U000342,
0113U003166
, R & D reports
Title
Establish new risk factors and to investigate their role in the stratification of medical tactics at different stages of multiple myeloma
popup.stage_title
Head
Maslyak Zvenyslava V.,
Registration Date
29-01-2016
Organization
LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE
popup.description2
The results of the study in 94 patients (pts) with multiple myeloma (MM) and two with acute plazmoblastic leukemia (APL), aged from 32 to 77 years. The 59 pts have treated the proteasome inhibitor bortezomib (B) as monotherapy, in scheme VD or with cytotoxic drugs, 33 pts in the first line and 26 pts - pre-treatment. It was found that the overall response rate was 86% regardless of line of therapy, however, the application of B in the first line is almost twice as likely to achieve complete and very good partial response, which is a predictor of long-term survival. Immunomodulatory drugs thalidomide (T) is also applied in 37 patients with MM in combination with dexamethasone, melphalan and prednisone or a modified scheme CTD. Summary response to T was similar, in a first line of treatment he was even higher (96%), whereas in the group of drug-resistant or after relapse by T, the total response was less when compared with a similar group-treated B: 75% vs. 86% . Karyotype analysis was performed in 39 pts with MM and both APL pts, cytogenetic changes were found in 47% of patients with prognostically unfavorable chromosomal aberrations totaled a third of all cases. Pro-inflammatory cytokines TNF, IL-6, IL-8 and proangiogenic factor VEGF were studied in 63 pts. The relationship of proinflammatory cytokines IL-6, TNF and to the duration of previous treatment of MM. The tendency to increase the concentration of IL-8 in patients resistant to bortezomib. It was shown that the major pro-angiogenic protein VEGF can be used as an independent marker of tumor progression, in a study which allows dynamics monitor response to treatment. The 22 MM pts were analyzed associations between metabolic disorders and disorders of hemostasis prognostic markers for the treatment of hemostatic complications.
Product Description
popup.authors
Виговська Ольга Ярославівна
Виговська Ярослава Іллівна
Гуменний Олександр Дмитрович
Даниш Ольга Йосипівна
Дзісь Іван Євгенович
Зозуля Тетяна Омелянівна
Лещук Остап Васильович
Лук'янова Анна Сергіївна
Лукавецький Лесь Миронович
Мельник Марія Іллярівна
Пеленьо Наталія Володимирівна
Сусіда Христина Романівна
Цяпка Орест Миколайович
popup.nrat_date
2020-04-02
